Skip links

RUDIA’S CAMPAIGN

Rudia is happy with the delayed decision she made in 2015 to go on a Phase I trial for a new CML drug – asciminib.

“It has turned out to be a really good thing to try and I’m happy I did it,” said Rudia.  

“I can’t pinpoint any side-effects it’s giving me. It’s the best drug of everything I’ve tried.” 

And Rudia has “tried nearly everything” since her diagnosis 18 years ago, just after her 30th birthday.  

She was working in her husband’s newly established business and raising her two young children; both have albinism and are visually impaired. 

“They were tough babies who never slept well and I was constantly exhausted,” said Rudia. 

She thought she had chronic fatigue syndrome, then a blood test revealed a high white cell count. After a bone marrow biopsy, just before Christmas 2001, she found out she had CML on December 29.  

“I was sure it would be negative and was obviously upset at the diagnosis,” said Rudia, now 48, of Adelaide. 

Imatinib (Glivec®) was being trialled at that time and wasn’t widely accessible, so she began treatment with hydroxyurea briefly before going on to interferon.  

That’s when Rudia began to get nerve pain, which has dominated her life ever since. It took many years to be diagnosed as severe neuropathic pain. She’s tried nearly every narcotic and pain is the main reason she has changed from one CML drug to another. 

This is Liquid Fancy heading element

Rudia endured “terrible side-effects” from interferon for 12 months until “the new drug” [imatinib] became available. 

She was on imatinib for two years before again, due to side-effects, she moved on to dasatinib (Sprycel®) which she was on “for a long time”. 

“It took 10 years before I eventually got to zero [CML undetectable in her bone marrow],” said Rudia, and she was able to have a break from treatment after having a 0.00 result for two years running. 

“I was experiencing such severe pain and I wanted to come off my drugs to see if it would make any difference, which it did,” she said.  

“He [Rudia’s haematologist] allowed me to do that, to try and understand what was happening with the pain. Even now, it’s a big mystery. 

“My doctor put me on a stop trial. I would never stop my drugs otherwise and I only did it with his consent,” said Rudia, who takes compliance to her CML treatment very seriously.  

 “But after six weeks, my CML levels got really high, so I had to start CML treatment again.”  

That’s when Rudia was told about the asciminib trial, but she opted to try nilotinib (Tasigna®) instead. 

“I could have gone on the trial drug I’m on now, but I didn’t want to,” said Rudia. 

“It hadn’t been tried in humans and I felt at the time that I didn’t need to put myself in that position, in case something did go wrong. 

“Most people who come off their drug and relapse, like I did, will achieve total zero again within about three months,” she said. 

But after 12 months on nilotinib, Rudia’s CML level still hadn’t returned to zero, and that’s when she changed her mind and decided to try asciminib. 

“I thought maybe it’s worth giving it a go,” said Rudia who joined the asciminib trial in mid-2015.  

“It was a bit scary because it was a Phase I trial. But by then people all round the world were on it. My doctor, who has conferences with other [trial] doctors every couple of weeks, didn’t feel it was a risky thing for me to do. 

“It’s a tablet you take once a day and a bit like nilotinib, you have to fast one hour before or two hours after a meal.  

“I take five tablets (200mg) before I go to sleep, so I don’t get nausea, and I take painkillers every day,” said Rudia. 

“I’ve taken 3½ years and two drugs to get another zero. At my last appointment, it went up to .013, but I had a couple of 0.00s before that,” she said. 

“My personal aim is to get to 0.00, stay there for two years, then trial coming off the drugs again.  

“I want to do that because I still have problems with my pain – it’s a constant thing that bothers me more than the leukaemia. And I know my pain significantly improves when I’m not on any drugs. 

“Where I’m sitting now, my [CML] levels are very low. There’s no problem with living like that and the drug isn’t giving me any new side-effects apart from pain and fatigue which have been ongoing issues,” said Rudia, who works six hours a day most weekdays, depending on how her health is at the time. 

“And even though I work, I am not actually that productive most days.” 

Leave a comment